Releases Details
Grant of Options
Released : February 17, 2021 17:44
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
|
Option Grants to PDMRs |
|
|
Doerfler, Doug |
390,200 |
|
Holtz, Ron |
177,600 |
|
Thompson, J. Stark |
26,900 |
|
Mandell, Art |
26,900 |
|
Erck, Stan |
26,900 |
|
Brooke, Will |
26,900 |
|
Johnston, John |
26,900 |
|
Douglas, Richard |
26,900 |
|
Total |
729,200 |
In the case of the Executive Directors and other employees, Option Grants vest 12/48th of the total grant one year after date of grant, and thereafter vest 1/48th per month for 36 months after the date of grant. Option Grants for Non-Executive Directors fully vest at the end of twelve (12) months after date of grant. The Option Grants have an exercise price of
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Grant of Options over Shares of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Exercise of options and Sale of Common Stock by PDMR |
|
|
d) |
Price(s) and volume(s) |
Doerfler, Doug - 390,200 at an exercise price of Holtz, Ron - 177,600 at an exercise price of Thompson, J. Stark - 26,900 at an exercise price of Mandell, Art - 26,900 at an exercise price of Erck, Stan - 26,900 at an exercise price of Brooke, Will - 26,900 at an exercise price of Johnston, John - 26,900 at an exercise price of Douglas, Richard - 26,900 at an exercise price of |
|
|
|
|
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
|
f) |
Date of the transaction |
16 February 2021 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL, MXCN) and is headquartered in
For further information, please contact:
|
|
|
||||||||||
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
